Biomolecular Condensates in Cancer: How Phase Separation Shapes Tumor Biology and Therapy Resistance

 

Biomolecular Condensates in Cancer: How Phase Separation Shapes Tumor Biology and Therapy Resistance

Introduction

Cancer biology has traditionally been understood through genetic mutations, abnormal signaling pathways, altered metabolism, immune interactions, and changes in the tumor microenvironment. However, an additional layer of cellular organization is attracting increasing attention: biomolecular condensates.

Inside cells, many proteins and RNA molecules do not simply remain uniformly distributed. Instead, they can gather into dynamic, membrane-free compartments that concentrate selected molecules and organize biochemical reactions. These structures are broadly known as biomolecular condensates.

One mechanism that can contribute to condensate formation is liquid-liquid phase separation (LLPS). Through this process, proteins, RNA, DNA-associated factors, and other biomolecules can separate into concentrated and less-concentrated phases under appropriate physical and biochemical conditions.

In cancer, abnormal regulation of these condensates may influence transcription, signal transduction, DNA damage responses, stress adaptation, metabolism, immune regulation, and other processes important for tumor development. Recent research has also connected dysregulated phase separation with therapeutic resistance.

This emerging field raises an important question:

Could understanding how cancer cells organize their molecular machinery reveal new vulnerabilities for precision oncology?

 

What Are Biomolecular Condensates?

Biomolecular condensates are dynamic, membrane-less cellular compartments that concentrate particular proteins, nucleic acids, and other molecules.

Unlike conventional organelles such as mitochondria or lysosomes, many condensates do not have a surrounding lipid membrane.

Instead, they can arise through networks of molecular interactions.

These interactions may involve:

• Protein–protein interactions
• Protein–RNA interactions
• RNA–RNA interactions
• Electrostatic interactions
• Multivalent binding
• Intrinsically disordered regions
• Post-translational modifications
• Changes in molecular concentration

Because condensates can rapidly assemble, exchange components, and dissolve, they provide cells with a flexible way to organize biochemical reactions in space and time.

 

Understanding Liquid-Liquid Phase Separation

Liquid-liquid phase separation (LLPS) is a physical process in which biomolecules within a mixed cellular environment separate into distinct phases.

A simplified example is the separation of oil and water, although biological LLPS is considerably more complex.

Within cells, proteins and nucleic acids can undergo numerous weak and multivalent interactions. When the concentration and interaction conditions are favorable, certain molecules can become enriched in a particular region, creating a condensate.

The process can be influenced by:

• Protein concentration
• RNA concentration
• Temperature
• pH
• Ionic conditions
• Post-translational modifications
• Molecular interactions
• Cellular stress

This dynamic behavior allows cells to create temporary molecular environments without building a conventional membrane-bound organelle.

 

Why Does Phase Separation Matter in Cancer?

Cancer cells must continuously adapt to changing conditions.

They need to:

• Maintain rapid growth
• Alter gene expression
• Respond to cellular stress
• Repair DNA damage
• Adapt to limited nutrients
• Escape immune surveillance
• Survive treatment
• Reorganize signaling pathways

Biomolecular condensates may help organize some of these processes.

When condensate formation or dissolution becomes abnormal, the resulting changes may alter the timing, location, and intensity of molecular reactions.

Research has linked dysregulated LLPS with several cancer-associated processes, including transcriptional control, signaling, DNA repair, immune regulation, and therapy resistance.

 

Biomolecular Condensates and Gene Regulation

Gene expression requires coordinated interactions between DNA, transcription factors, cofactors, RNA polymerase, chromatin regulators, and RNA molecules.

These components can form highly organized molecular environments.

In some settings, transcription factors and coactivators can participate in condensate formation near regulatory DNA regions such as super-enhancers.

These transcriptional condensates may concentrate the machinery required for active gene expression.

In cancer, abnormal transcriptional condensate formation has been associated with dysregulated expression of genes that support malignant cell states.

 

Super-Enhancers and Cancer

Super-enhancers are regulatory regions associated with strong transcriptional activity and cell-identity programs.

Many cancer cells depend on abnormal transcriptional programs to maintain proliferation and survival.

Phase separation provides one model for understanding how transcription factors, coactivators, and RNA polymerase-associated machinery can become concentrated at regulatory regions.

This may help explain how certain oncogenic gene-expression programs remain highly active.

Research into super-enhancer-associated condensates is therefore providing new perspectives on transcriptional regulation in cancer.

 

Transcriptional Condensates and Tumor Growth

Cancer cells often depend on persistent activation of specific transcriptional programs.

Transcriptional condensates may help organize these molecular interactions.

Potential consequences of abnormal transcriptional condensates include:

• Sustained oncogene expression
• Altered cell identity
• Increased proliferation
• Cellular plasticity
• Survival under stress
• Changes in differentiation
• Adaptation to treatment

These relationships are complex and vary between cancer types. Nevertheless, understanding transcriptional condensates may provide new insight into how cancer cells maintain malignant states.

 

Biomolecular Condensates and Cell Signaling

Cell signaling depends on bringing the right molecules together at the right time and location.

Condensates can provide temporary molecular platforms where signaling proteins become concentrated.

This can influence:

• Signal strength
• Signal duration
• Protein interactions
• Pathway activation
• Cellular responses

Emerging research has connected phase separation with pathways involved in cancer biology, including Wnt/β-catenin, Hippo/YAP, TGF-β, cGAS-STING, and cAMP/PKA signaling.

This does not mean that every signaling pathway is controlled exclusively through phase separation. Rather, condensates can represent one regulatory layer within larger signaling networks.

 

Condensates and DNA Damage Response

Cancer cells experience substantial genomic stress.

DNA damage can arise from:

• Replication stress
• Reactive oxygen species
• Radiation
• Chemotherapy
• Oncogene-driven replication abnormalities

Cells respond by activating sophisticated DNA damage detection and repair systems.

Biomolecular condensates have been implicated in organizing proteins involved in DNA damage response and repair.

By concentrating repair factors near damaged DNA, condensates may help coordinate molecular events required for genome maintenance.

In cancer, abnormal regulation of these processes could potentially contribute to genomic instability or treatment adaptation.

 

Biomolecular Condensates and Cancer Cell Stress

Tumor cells frequently experience stressful conditions.

These include:

• Hypoxia
• Nutrient limitation
• Oxidative stress
• Proteotoxic stress
• DNA damage
• Therapeutic exposure

Cells can respond by reorganizing RNA and protein molecules into stress-associated condensates.

For example, stress granules are dynamic RNA–protein assemblies associated with cellular stress responses.

By temporarily reorganizing molecular components, condensates may help cells survive unfavorable conditions.

In cancer, enhanced stress adaptation may contribute to tumor-cell survival and treatment resistance.

 

Phase Separation and Cancer Therapy Resistance

One of the most actively developing areas of research is the connection between LLPS and therapy resistance.

Recent reviews describe several possible mechanisms through which dysregulated condensates may support resistance, including:

• Sustaining oncogenic transcription
• Altering DNA damage responses
• Supporting cancer-cell survival
• Modulating immune signaling
• Promoting cellular plasticity
• Influencing cancer stem-like states
• Altering drug-associated molecular environments

These mechanisms may allow cancer cells to adapt to therapeutic pressure.

Importantly, this is an emerging research field. Condensate biology should not currently be considered a routine clinical method for predicting treatment response.

 

Biomolecular Condensates and Cancer Stemness

Cancer stem-like cells can exhibit properties such as:

• Self-renewal
• Cellular plasticity
• Treatment tolerance
• Tumor initiation capacity

Recent research has begun investigating whether phase-separated molecular assemblies contribute to the regulatory programs supporting these properties.

By organizing transcriptional and signaling machinery, condensates may influence cell-state transitions.

This creates a potential connection between phase separation, cancer plasticity, and therapy resistance.

 

Condensates and Immune Evasion

Cancer cells interact continuously with the immune system.

To survive, tumors may develop mechanisms that:

• Suppress immune activation
• Alter antigen presentation
• Modify inflammatory signaling
• Influence immune checkpoints
• Reshape the tumor microenvironment

Emerging evidence suggests that phase separation can influence immune-related pathways, including cGAS-STING signaling and other regulatory networks.

Recent reviews are also examining the interaction between LLPS and the tumor microenvironment, including possible relationships with immune regulation and treatment resistance.

 

Phase Separation and the Tumor Microenvironment

The tumor microenvironment contains:

• Cancer cells
• Fibroblasts
• Immune cells
• Blood vessels
• Extracellular matrix
• Signaling molecules
• Metabolic factors

These components create a highly dynamic environment.

Recent research is exploring how tumor-microenvironment conditions may influence condensate formation and, conversely, how condensate biology may affect tumor–microenvironment interactions.

This creates a potentially important feedback relationship:

Tumor microenvironment → molecular conditions → condensate behavior → cellular response → tumor progression

However, accurately measuring condensate behavior inside living tumors remains challenging.

 

RNA and Biomolecular Condensates

RNA is an important component of many biomolecular condensates.

RNA molecules can interact with proteins and influence:

• Condensate formation
• Condensate stability
• RNA processing
• Translation
• Transcription
• Cellular stress responses

RNA-binding proteins containing intrinsically disordered regions can participate in dynamic molecular interactions that support condensate formation.

Changes in RNA expression, processing, or modification may therefore influence condensate behavior in cancer.

 

Intrinsically Disordered Regions and Condensate Formation

Many proteins involved in condensate formation contain intrinsically disordered regions (IDRs).

Unlike rigid protein domains, IDRs can adopt flexible conformations and participate in multiple weak interactions.

These properties can support the multivalent interactions required for phase separation.

Cancer-associated mutations or changes in protein regulation may alter these interactions and consequently change condensate behavior.

Understanding IDRs is therefore an important part of studying the molecular basis of cancer-associated phase separation.

 

Post-Translational Modifications and Condensates

Post-translational modifications (PTMs) can change protein behavior.

Examples include:

• Phosphorylation
• Acetylation
• Methylation
• Ubiquitination
• SUMOylation

These modifications can alter molecular interactions, localization, stability, or activity.

Because condensate formation depends on molecular interactions, PTMs can potentially influence whether a protein enters, leaves, forms, or dissolves a condensate.

Recent cancer research is investigating how abnormal PTM patterns may contribute to dysregulated LLPS.

 

Biomolecular Condensates and Epigenetic Regulation

Cancer frequently involves abnormal epigenetic regulation.

Changes in:

• Chromatin organization
• Histone modifications
• DNA methylation
• Transcription-factor activity
• Chromatin accessibility

can alter gene expression.

Phase separation may contribute to the spatial organization of some transcriptional and chromatin-associated processes.

This creates an emerging intersection between:

Epigenetics + Chromatin Biology + Phase Separation + Cancer

Understanding this relationship could provide new insights into how cancer cells establish and maintain abnormal gene-expression states.

 

Condensates and Oncogenic Fusion Proteins

Some cancers contain abnormal fusion proteins produced by chromosomal rearrangements.

Certain fusion proteins can alter transcriptional regulation and signaling.

Emerging research suggests that some oncogenic fusion proteins can participate in aberrant condensate formation, potentially reorganizing transcriptional machinery and promoting cancer-associated gene expression.

This provides another example of how structural changes in cancer-associated proteins can influence cellular organization.

 

Can Biomolecular Condensates Be Therapeutic Targets?

One of the most exciting questions is whether cancer-associated condensates can be therapeutically manipulated.

Potential strategies include:

• Disrupting abnormal condensate formation
• Altering condensate stability
• Changing protein concentration
• Modifying relevant post-translational modifications
• Targeting condensate-associated proteins
• Altering molecular interactions
• Exploiting cancer-specific condensate dependencies

Recent reviews describe pharmacological targeting of oncogenic condensates as an emerging research direction.

However, this approach remains largely investigational.

 

Why Targeting Condensates Is Challenging

A major challenge is that condensates are not inherently harmful.

Many normal cellular processes depend on them.

Therefore, simply eliminating condensates could interfere with healthy cellular functions.

The challenge is to distinguish:

Normal physiological condensates

from

Cancer-associated or oncogenic condensates.

Future therapies may need to target cancer-specific molecular dependencies rather than globally suppress phase separation.

 

Condensate Properties May Matter

Researchers are studying not only whether a condensate forms, but also its physical characteristics.

Important properties may include:

• Size
• Shape
• Molecular composition
• Concentration
• Dynamics
• Material state
• Molecular exchange
• Stability
• Response to cellular conditions

Some condensates may behave more like dynamic liquids, while others can mature into more stable or gel-like assemblies.

Understanding these properties may be important for developing therapies that selectively alter abnormal condensate behavior.

 

Advanced Imaging for Condensate Research

Studying biomolecular condensates requires sophisticated imaging technologies.

Researchers can use approaches such as:

• Live-cell fluorescence microscopy
• Super-resolution microscopy
• Single-molecule imaging
• Quantitative microscopy
• Fluorescence recovery after photobleaching
• Spatial imaging
• Biophysical measurements

These approaches help researchers observe condensate formation, molecular exchange, localization, and dynamics.

However, distinguishing genuine biological phase separation from other forms of molecular clustering remains an important experimental challenge.

 

AI and Computational Analysis

AI and computational biology may increasingly contribute to condensate research.

Machine-learning approaches could help analyze:

• Microscopy images
• Protein sequences
• Intrinsically disordered regions
• Molecular interactions
• Condensate morphology
• Protein localization
• Multi-omics datasets

Combining computational predictions with experimental validation may help identify proteins and molecular pathways that are likely to participate in cancer-associated condensates.

AI predictions, however, need appropriate laboratory and clinical validation before they can support therapeutic decisions.

 

Biomolecular Condensates and Precision Oncology

Precision oncology aims to match treatment strategies with the biological characteristics of individual tumors.

Traditionally, this includes:

• Genomic alterations
• Gene expression
• Protein biomarkers
• Tumor mutations
• Immune characteristics

Condensate biology could potentially add another layer:

How does the tumor organize its molecular machinery?

A future precision-oncology framework could potentially integrate:

Genomics + Transcriptomics + Proteomics + Spatial Biology + Imaging + Condensate Biology

This may help researchers identify tumors that depend on specific molecular assemblies or phase-separated signaling mechanisms.

 

Biomolecular Condensates and Drug Discovery

Condensate biology could also influence the way new cancer drugs are discovered.

Researchers may investigate compounds that:

• Prevent pathological condensate formation
• Disrupt protein–protein interactions
• Change condensate material properties
• Alter condensate localization
• Modify condensate-associated proteins
• Exploit cancer-specific condensate dependencies

Another possibility is that existing drugs may influence condensate behavior indirectly through their effects on signaling or protein modification.

This area is still developing, and substantial work is needed to determine which approaches can be translated into safe and effective cancer therapies.

 

Challenges in Biomolecular Condensate Research

Despite rapid progress, several challenges remain.

1. Condensates are highly dynamic

Their composition and physical properties can change rapidly.

2. In-vitro and in-vivo behavior can differ

A condensate observed in a laboratory system may not behave identically inside a living tumor.

3. Phase separation can be difficult to prove

Not every molecular cluster is necessarily the result of LLPS.

4. Tumor heterogeneity

Different cancer cells within the same tumor may exhibit different condensate behaviors.

5. Technical limitations

Directly measuring condensates in living human tumors remains difficult.

6. Therapeutic selectivity

Targeting cancer-associated condensates without disrupting normal cellular condensates is a major challenge.

7. Clinical validation

Most condensate-targeting approaches remain in preclinical or early research stages.

Recent literature specifically highlights the difficulty of monitoring condensate dynamics in vivo and the need for improved imaging and single-cell approaches.

 

The Future of Biomolecular Condensates in Cancer Research

The field is moving toward increasingly integrated approaches.

Future research may combine:

• Single-cell biology
• Spatial biology
• Proteomics
• Transcriptomics
• Structural biology
• Live-cell imaging
• Biophysical measurements
• AI
• Drug discovery

This could help researchers understand how molecular condensates vary between individual cancer cells and how they change during treatment.

Another important direction is identifying condensate vulnerabilities that are unique to particular cancer types or molecular subgroups.

If successful, such approaches could contribute to more selective therapeutic strategies.

 

From Molecular Organization to Therapeutic Vulnerability

One of the most interesting ideas emerging from condensate research is that cellular organization itself may become a therapeutic vulnerability.

Cancer cells can become dependent on specific transcriptional or signaling environments.

If a tumor relies heavily on a particular condensate to maintain an oncogenic program, disrupting that dependency could potentially weaken the malignant state.

This concept is still being tested experimentally, but it offers a different perspective on targeted cancer therapy.

Instead of targeting only:

A mutation → a protein → a pathway

researchers may eventually target:

A molecular assembly → a cellular state → a cancer dependency

 

Why Biomolecular Condensates Matter for Future Oncology

Cancer is not simply a collection of mutated genes.

It is a dynamic biological system in which molecular interactions, cellular organization, tissue environment, and physical conditions continuously influence one another.

Biomolecular condensates provide a framework for understanding how cells organize complex molecular processes without relying entirely on membrane-bound compartments.

In cancer, abnormal condensate behavior may influence:

• Gene regulation
• Oncogenic signaling
• DNA repair
• Cellular stress
• Immune regulation
• Tumor progression
• Cancer plasticity
• Therapy resistance

As this field develops, it may provide new ways to understand cancer biology and identify therapeutic opportunities.

 

Conclusion

Biomolecular condensates are emerging as an important layer of cancer biology.

Through processes such as liquid-liquid phase separation, proteins and nucleic acids can become organized into dynamic, membrane-less compartments that regulate cellular reactions.

In cancer, abnormal condensate behavior may influence transcription, signaling, DNA damage response, stress adaptation, immune regulation, and treatment resistance.

The growing connection between phase separation and cancer therapy resistance is particularly important. Recent research is investigating whether oncogenic condensates can be pharmacologically manipulated to create new therapeutic vulnerabilities.

At the same time, important questions remain about how condensates form in living tumors, how their properties vary between patients, and how cancer-specific condensates can be targeted without disrupting essential normal cellular functions.

The future of precision oncology may therefore extend beyond mutations and biomarkers to include the physical and organizational architecture of molecular processes inside cancer cells.

 

Join Oncology Summit-2027

The International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027) brings together researchers, oncologists, clinicians, scientists, healthcare professionals, and industry experts to discuss emerging developments in cancer research and cancer care.

📅 March 25–27, 2027
📍 Osaka, Japan

The summit provides an international platform to exchange research, explore emerging technologies, discuss innovative therapeutic strategies, and connect with experts working across oncology and cancer care.

Join global experts at Oncology Summit-2027 and share your research with the international oncology community.

Frequently Asked Questions (FAQs)

1. What are biomolecular condensates?

Biomolecular condensates are dynamic, membrane-less cellular compartments that concentrate specific proteins, RNA, and other biomolecules to organize biochemical processes.

2. What is liquid-liquid phase separation?

Liquid-liquid phase separation is a physical process in which biomolecules separate into concentrated and less-concentrated phases, allowing the formation of dynamic molecular condensates.

3. How are biomolecular condensates related to cancer?

Abnormal condensate formation or regulation may influence gene expression, signaling, DNA repair, cellular stress responses, immune regulation, and other processes involved in cancer biology.

4. What are transcriptional condensates?

Transcriptional condensates are molecular assemblies associated with transcriptional machinery. They can concentrate transcription factors, coactivators, and other regulatory components near active genomic regions.

5. Can phase separation promote cancer progression?

Emerging evidence suggests that dysregulated phase separation can contribute to cancer-associated processes such as abnormal transcription, oncogenic signaling, genome maintenance defects, and cellular adaptation.

6. Can biomolecular condensates contribute to therapy resistance?

Yes. Recent reviews have described several possible mechanisms linking dysregulated LLPS with cancer therapy resistance, including altered transcription, DNA damage responses, immune regulation, and cancer-cell adaptation.

7. Can biomolecular condensates be targeted with cancer drugs?

Researchers are actively investigating this possibility. Strategies include altering condensate formation, stability, molecular interactions, or associated proteins. However, most condensate-targeting approaches remain investigational.

8. What role does RNA play in biomolecular condensates?

RNA can interact with proteins and contribute to the formation, organization, and regulation of condensates. RNA–protein interactions are particularly important in several cellular condensates.

9. What are intrinsically disordered regions?

Intrinsically disordered regions are flexible protein regions that lack a single stable three-dimensional structure. Their ability to participate in multiple molecular interactions can contribute to condensate formation.

10. Are biomolecular condensates already used routinely in cancer treatment?

No. Although condensate biology is a rapidly developing research field, biomolecular condensates are not currently a routine clinical treatment or standard diagnostic tool.

11. How are researchers studying biomolecular condensates?

Researchers use live-cell microscopy, fluorescence imaging, super-resolution microscopy, biochemical experiments, biophysical techniques, computational analysis, and increasingly sophisticated spatial and single-cell approaches.

12. What is the future of biomolecular condensates in precision oncology?

Future research may investigate whether condensate characteristics can help identify cancer dependencies, treatment vulnerabilities, or patient-specific therapeutic strategies. Further experimental and clinical validation is required.